Pan‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma

The pan‑immune‑inflammation‑value (PIV) is a comprehensive biomarker that integrates different peripheral blood cell subsets. The present study aimed to evaluate the prognostic ability of PIV in patients with nasopharyngeal carcinoma (NPC) undergoing chemoradiotherapy. PIV was assessed using the following equation: (Neutrophil count x platelet count x monocyte count)/lymphocyte count. The Kaplan‑Meier method and Cox hazards regression models were used for survival analyses. The optimal cut‑off values for PIV and systemic immune‑inflammation index (SII) were determined using receiver operating characteristic analysis to be 428.0 and 1032.7, respectively. A total of 319 patients were recruited. Patients with a low baseline PIV (≤428.0) accounted for 69.9% (n=223) and patients with a high baseline PIV (>428.0) accounted for 30.1% (n=96). Compared with patients with low PIV, patients with a high PIV had significantly worse 5‑year progression‑free survival PFS; 66.8 vs. 77.1%; hazard ratio (HR), 1.97; 95% confidence interval (CI), 1.22‑3.23); P=0.005 and 5‑year overall survival (OS; 68.7 vs. 86.9%, HR, 2.71; 95% CI, 1.45‑5.03; P=0.001). PIV was also a significant independent prognostic indicator for OS (HR, 2.19; 95% CI, 1.16‑4.12; P=0.016) and PFS (HR, 1.86; 95% CI, 1.14‑3.04; P=0.013) and outperformed the SII in multivariate analysis. In conclusion, the PIV was a powerful predictor of survival outcomes and outperformed the SII in patients with NPC treated with chemoradiotherapy. Prospective validation of the PIV should be performed to better stratify radical treatment of patients with NPC.